biostudies-literatureLei JCancer Research UKBreast Cancer NowThe Francis Crick InstituteDutch Research Council (NWO)NCI NIH HHSCIHR18https://www.ebi.ac.uk/biostudies/studies/S-EPMC4374346biostudies-literatureUnknown17<h4>Introduction</h4>Tumor lymphocyte infiltration is associated with clinical response to chemotherapy in estrogen receptor (ER) negative breast cancer. To identify variants in immunosuppressive pathway genes associated with prognosis after adjuvant chemotherapy for ER-negative patients, we studied stage I-III invasive breast cancer patients of European ancestry, including 9,334 ER-positive (3,151 treated with chemotherapy) and 2,334 ER-negative patients (1,499 treated with chemotherapy).<h4>Methods</h4>We pooled data from sixteen studies from the Breast Cancer Association Consortium (BCAC), and employed two independent studies for replications. Overall 3,610 single nucleotide polymorphisms (SNPs) in 133 genes were genotyped as part of the Collaborative Oncological Gene-environment Study,Breast cancer research : BCRAssessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy.PMC4374346C5047/A10692U01 CA116167C1275/A9896P50 CA159981U19 CA148537C12292/A11174C1287/A10118C1281/A12014C1287/A10710184.021.007R01 CA128978R01 CA116167UM1 CA164920U19 CA1480651U19 CA1480651U19 CA14853716561CA1767851656516563R01 CA176785C490/A10124R01 CA126841P50 CA1162012010NOVPR62C1287/A12014C5047/A8384CA116201CA116167U19 CA148112CA1289781012415956C5047/A15007Shah MKosma VMGarcia-Closas MAndrulis ILKristensen VNVachon CMatsuo KJager APhillips KASeibold PAlnæs GIWang QKang DBlomqvist CIto HEaston DFPharoah PPCouch FJMuranen TAChenevix-Trench GTapper WJAittomaki KTilanus-Linthorst MMYip CHBolla MKChanock SJUlmer HUHartikainen JMEilber ULi JEkici ABChang-Claude JShen CYWu PETaib NARudiger TFasching PANord SSucheston LETeo SHHooning MJHall PCornelissen STajima KSchmidt MKHumphreys KEccles DNevanlinna Hvan Deurzen CHFigueroa JLinn SKataja VRafiq SHsiung CNRudolph AHallberg ELei JGlendon GWildiers HHo GFBenitez JBeckmann MWTorres DYoo KYBorresen-Dale ALSmeets ABehrens SPark SKHatse SLuben RCzene KKnight JAMargolin SHou MFMoysich KBHaeberle LTchatchou SDennis JLindblom AIwata HOlson JELambrechts DChoi JYMaishman THamann UkConFab InvestigatorsLissowska JDunning AMMannermaa AGoode ELvan den Broek SAfalseAssessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy.<h4>Introduction</h4>Tumor lymphocyte infiltration is associated with clinical response to chemotherapy in estrogen receptor (ER) negative breast cancer. To identify variants in immunosuppressive pathway genes associated with prognosis after adjuvant chemotherapy for ER-negative patients, we studied stage I-III invasive breast cancer patients of European ancestry, including 9,334 ER-positive (3,151 treated with chemotherapy) and 2,334 ER-negative patients (1,499 treated with chemotherapy).<h4>Methods</h4>We pooled data from sixteen studies from the Breast Cancer Association Consortium (BCAC), and employed two independent studies for replications. Overall 3,610 single nucleotide polymorphisms (SNPs) in 133 genes were genotyped as part of the Collaborative Oncological Gene-environment Study,2015-01-01T00:00:00Z2015 Feb2026-06-08T03:31:17.203Z2026-06-08T03:14:29.972ZS-EPMC43743462584932710.1186/s13058-015-0522-2